NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

News Market Reaction – NGM

The recorded move for NGM in the trading session of this news was -0.75%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/17/2024 - 04:47 PM EST

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer, will participate in the B. Riley Securities 4^th Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 18^th, at 2:30 pm ET.

A replay of the presentation will be available under the Investors and Media section of NGM Bio’s website at https://ir.ngmbio.com/events-presentations and will be archived on NGM Bio’s site for at least 30 days following the event.

About NGM Bio

NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. NGM Bio’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. Visit us at www.ngmbio.com for more information.